• 1. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 2. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 3. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 4. Enabling stable MnO2 matrix for aqueous zinc-ion battery cathodes?
  Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082
• 5. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207

Research Briefing on 5-(hydroxymethyl)-3-[(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one (CAS: 41359-15-3)

Recent advancements in the field of chemical biology and medicinal chemistry have highlighted the significance of nitrofuran derivatives, particularly 5-(hydroxymethyl)-3-[(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one (CAS: 41359-15-3). This compound has garnered attention due to its potential antimicrobial and antiparasitic properties, making it a promising candidate for further pharmaceutical development. The following briefing synthesizes the latest research findings on this compound, focusing on its synthesis, biological activity, and potential applications.

The compound, characterized by its unique oxazolidinone scaffold and nitrofuran moiety, has been investigated for its mechanism of action against various pathogens. Recent studies suggest that its antimicrobial activity is mediated through the inhibition of bacterial DNA synthesis, particularly in Gram-positive and anaerobic bacteria. Additionally, its nitro group reduction within microbial cells generates reactive intermediates that contribute to its cytotoxic effects. These findings underscore its potential as a broad-spectrum antimicrobial agent.

In terms of synthesis, recent methodologies have focused on optimizing the yield and purity of 5-(hydroxymethyl)-3-[(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one. A 2023 study published in the Journal of Medicinal Chemistry reported a novel one-pot synthesis route, achieving a 78% yield with high enantiomeric purity. This advancement is critical for scaling up production and facilitating further preclinical studies. The study also highlighted the compound's stability under physiological conditions, a key factor for its pharmacokinetic profile.

Preclinical evaluations have demonstrated promising results. In vitro assays against drug-resistant bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE), revealed minimum inhibitory concentrations (MICs) in the range of 2-8 μg/mL. Furthermore, in vivo murine models of bacterial infection showed a significant reduction in bacterial load following treatment with the compound, with no observable toxicity at therapeutic doses. These results position it as a viable candidate for combating antibiotic-resistant infections.

Beyond antimicrobial applications, emerging research has explored its potential in antiparasitic therapy. A 2024 study in Antimicrobial Agents and Chemotherapy reported its efficacy against Trypanosoma cruzi, the causative agent of Chagas disease. The compound exhibited a 90% reduction in parasite load at a concentration of 10 μM, outperforming existing nitroheterocyclic drugs. This finding opens new avenues for repurposing the compound in neglected tropical diseases.

Despite these promising results, challenges remain. The compound's solubility and bioavailability require further optimization to enhance its therapeutic index. Additionally, comprehensive toxicology studies are needed to assess long-term safety. Current research efforts are directed toward structural modifications, such as prodrug formulations, to address these limitations. Collaborative initiatives between academia and industry are expected to accelerate its translation into clinical trials.

In conclusion, 5-(hydroxymethyl)-3-[(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one represents a multifaceted therapeutic agent with significant potential in antimicrobial and antiparasitic applications. Continued research and development are essential to unlock its full clinical utility and address the growing global challenge of drug-resistant infections.

• 1217222-76-8(Furazolidone-D4)
• 67-45-8(Furazolidone)
• 1015855-64-7(Furaltadone-D5)
• 139-91-3(Furaltadone)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)